Sign up Australia
Proactive Investors - Run By Investors For Investors

Regeneus shares rise as results show Sygenus gel successfully fights acne

In a tough day across the ASX last Tuesday, Regeneus shares were up 14% to $0.12.
Girl popping pimple
Regeneus has patents in Australia, Europe, China, Japan and the US

Regeneus Ltd (ASX:RGS) has received promising results indicating that the topical use of Sygenus gel for six weeks in adults with acne was well tolerated.

The study also showed a significant effect on the appearance of acne lesions as early as three weeks.

Sygenus is a patented allogeneic cell secretions technology platform that comprises cytokines, growth factors and exosomes from adipose-derived mesenchymal stem cells.

Bioactive molecules reduce pain and inflammation

Bioactive molecules work to reduce pain and inflammation and encourage accelerated healing and repair.

The tolerance study, performed by RCTS, a dermatology testing company in Texas, examined the tolerability of Sygenus in 33 healthy volunteers with mild to moderate facial acne.

The study endpoints to assess tolerability involved the change in acne lesions over the 6-week period when Sygenus gel was applied topically twice a day.

Overall improvement achieved as early as three weeks

No intolerance was observed and there was an overall improvement in the appearance of acne, as early as 3 weeks.

Statistically significant reductions in the total number of inflammatory and non-inflammatory acne lesions were noted from baseline to week 6.

The acne global severity score also showed significant reduction (improvement) at week 6 compared to baseline.

Strong demand for new acne treatments

These promising results will help in the partnering of Sygenus gel for the acne market and other inflammatory skin conditions.

With few treatment innovations or improvements without significant side effects in the treatment of acne over the last 10 years, the demand for improved acne treatments is high.

Regeneus has patents in Australia, Europe, China, Japan and the US covering the composition, manufacture and use of Sygenus technology for the topical treatment of acne.

The company also has patent applications for the use of Sygenus for a broad range of other inflammatory skin conditions.

Potential pain relief applications

A key area of research focus is the use of Sygenus technology for the treatment of pain.

A preclinical post-operative pain study has shown that topical application of Sygenus has significant and longer lasting analgesic effects than an injection of morphine.

READ: Regeneus finds impressive pain relief properties in Sygenus

Regeneus is also investigating the use of its stem cell technologies for the treatment of pain in an ARC Linkage program with the University of Adelaide and Macquarie University.

View full RGS profile View Profile

Regeneus Ltd Timeline

Related Articles

lupus poster
January 18 2018
The last of the 200 patients has had their final assessment and the data is now being processed and analysed
affimer technology
May 01 2018
The company is making progress with its lead immuno-oncology programmes
m&a icon of bug fish swallowing big fish
December 04 2017
It is paying an initial US$13mln for Vamousse, which it is acquiring from TyraTech, the AIM-listed developer of the range. This will be followed by a deferred pay-out of as much as US$4.5mln based on sales targets

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use